The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

British Journal of Cancer

Volumn 96, Issue 6, 2007, Pages 1001-1007

  Giotopoulos, G ^a   Symonds, R P ^a   Foweraker, K ^a   Griffin, M ^b   Peat, I ^a   Osman, A ^a   Plumb, M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Fibrosis; Radiation injury; Telangiectasia; TGF 1; XRCC1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALLELE; ARTICLE; BREAST ATROPHY; BREAST CANCER; BREAST FIBROSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DAMAGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SINGLE NUCLEOTIDE POLYMORPHISM; TELANGIECTASIA; UNITED KINGDOM; VASCULAR ENDOTHELIUM;

ATROPHY; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION INJURIES; RADIATION PNEUMONITIS; TELANGIECTASIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33947386671     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603637     Document Type: Article

References (44)

1. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J, Yarnold J (2005) TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75: 18-21
2. Andreassen CN, Alsner J, Overgaard M, Overgaard J (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69: 127-135
3. Andreassen CN, Alsner J, Overgaard M, Sorensen FP, Overgaard J (2006) Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from paraffin embedded tissue samples. Int J Radiat Biol 82: 577-586
4. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL (1997) Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37: 253-258
5. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV (1988) Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014-1020
6. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Borger W, Jager J, Hoogenraad W, Collette L, Pierart M, for the European Organization for Research and Treatment of Cancer, Radiotherapy and Breast Cancer Groups (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiotherapy. N Eng J Med 345: 1378-1387
7. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, Williams J (2003) Normal tissue effects: reporting and analysis. Sem Radiat Oncol 13: 189-202
8. Bentzen SM, Overgaard M (1991) Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol 20: 159-165
9. Bentzen SM, Overgaard M, Overgaard J (1993) Clinical correlations between late normal tissue endpoints after radiotherapy: implications for predictive assays of radiosensitivity. Eur J Cancer 29A: 1373-1376
10. Brem R, Cox DG, Chapot B, Moullan N, Romestaing P, Gerard JP, Pisani P, Hall J (2006) The XRCC1 -77T>C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27: 2469-2474
11. Chang-Claude J, Popanda O, Tan X-L, Kropp S, Helmbold I, von Fournier D, Hasse W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB (2005) Association between polymorphisms in the DNA repair genes, XRCC1, APE1 and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11: 4802-4809
12. Clouthier DE, Comerford SA, Hammer RE (1997) Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100: 2697-2713
13. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346
14. CR-UK: Cancer Research UK (2004) Cancer Monographs. In Toms JR (ed)
15. De Ruyck K, Van Eikeren M, Claes K, Bacher K, Vral A, de Neve W, Thierens H (2006) TGFb1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65: 1240-1248
16. De Ruyck K, Van Eikeren M, Claes K, Morthier R, De Paepe A, Vral A, De Ridder L, Thierens H (2005) Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 gene and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 62: 1140-1149
17. EBCTCG: Early Breast Cancer Trialists' Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrences after 15 year survival; an overview of the randomised trials. Lancet 366: 2087-2106
18. El-Gamel A, Awad MR, Hasleton PS, James Hutchinson J, Yonan N, Egan J, Colin Campbell C, Rahman A, Sheldon S, Deiraniya A, Ian V, Hutchinson IV (1999) Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 18: 517-523
19. Fernet M, Hall J (2005) Genetic markers of therapeutic radiation sensitivity. DNA Repair 3: 1237-1243
20. Fiets WE, van Helvoirt RP, Nortier JWR, van der Tweel I, Struikmans H (2003) Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients: a prospective, comparative, non-randomised study. Eur J Cancer 39: 1081-1088
21. Gauldie J, Galt T, Bonniaud P, Robbins C, Kelly M, Warburton D (2003) Transfer of the active form of transforming growth factor-beta 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am J Pathol 163: 2575-2584
22. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Tim D, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8: 93-97
23. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD (2001) Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22: 917-922
24. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S (2004) New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for Spina Bifida acting in mothers during pregnancy? Am J Med Genetics 124: 339-345
25. Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright R, Morgan GJ, Wild CP (2002) Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. Br J Haematol 116: 587-594
26. Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S (1999) TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 84: 155-159
27. Linnebank M, Schmidt S, Kolsch H, Linnebank A, Heun R, Schmidt-Wolf IGH, Glasmacher A, Fliessbac AK, Klockgether T, Schlegel U, Pels H (2004) The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 90: 1969-1971
28. Martin M, Lefaix J, Delanian S (2000) TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 47: 277-290
29. Martin M, Vozenin MC, Gault N, Crechet F, Pfarr CM, Lefaix JL (1997) Coactivation of AP-1 activity and TGF-beta1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 15: 981-989
30. Mauch C, Kreig T (1990) Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 16: 93-107
31. McDermott DH, Halcox JPJ, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM (2001) Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89: 401-407
32. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J (2003) Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12: 1168-1174
33. NCRN Trial Standardisation of Breast Radiotherapy (1998) Clinical Trials and Statistics Unit. Sutton, Surrey, UK: Institute of Cancer Research
34. O'Sullivan B, Levin W (2003) Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol 13: 274-289
35. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, Gonzales-Gonzales D, Horiot JC, Bolla M, Bartelink H (1995) Late effects toxicity scoring: the SOMA scale. Radiother Oncol 35: 11-15
36. Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart A, Magee B, Kumar S. (2003) Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79: 137-143
37. Quarmby S, Kumar P, Kumar S (1999) Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Int J Cancer 82: 385-395
38. Randall K, Coggle JE (1995) Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. Int J Radiat Biol 68: 301-309
39. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS (1995) Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 2572-2576
40. Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G, Barr L, Baaildam A, Howell A, Royle G, Easton D, Eeeles R (2006) Acute chemotherapy-related toxicity is not increased in BRCA1 and BRACA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 12: 7033-7038
41. Sokal RR, Rohlf FJ (1995) In Biometry, 3rd edn, New York, USA: W.H. Freeman and Company
42. Terrell TG, Working PK, Chow CP, Green JD (1993) Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits. Int Rev Exp Pathol 34: 43-67
43. Van der Kogel AJ (1993) Radiobiology of normal tissues. In Basic Clinical Radiobiology Steel GG (ed) pp 99-107, London: Arnold
44. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M (1991) Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res 51: 3590-3594